Abstract

Despite the fact that vaccine resistance has been typically considered a rare phenomenon, some episodes of vaccine failure have been reported with increasing frequency in intensively-raised livestock. Infectious bronchitis virus (IBV) is a widespread avian coronavirus, whose control relies mainly on extensive vaccine administration. Unfortunately, the continuous emergence of new vaccine-immunity escaping variants prompts the development of new vaccines. In the present work, a molecular epidemiology study was performed to evaluate the potential role of homologous vaccination in driving IBV evolution. This was undertaken by assessing IBV viral RNA sequences from the ORF encoding the S1 portion of viral surface glycoprotein (S) before and after the introduction of a new live vaccine on broiler farms in northern-Italy. The results of several biostatistics analyses consistently demonstrate the presence of a higher pressure in the post-vaccination period. Natural selection was detected essentially on sites located on the protein surface, within or nearby domains involved in viral attachment or related functions. This evidence strongly supports the action of vaccine-induced immunity in conditioning viral evolution, potentially leading to the emergence of new vaccine-escape variants. The great plasticity of rapidly-evolving RNA-viruses in response to human intervention, which extends beyond the poultry industry, is demonstrated, claiming further attention due to their relevance for animal and especially human health.

Highlights

  • Avian infectious bronchitis is a well-recognized and widespread disease, which entails remarkable economic losses to the poultry industry by inducing respiratory and reproductive signs, decreased productive performances and increased mortality, when nephropathogenic strains or secondary infections are involved [1].The etiological agent, avian infectious bronchitis virus (IBV), is a member of the species avian Coronavirus, order Nidovirales, suborder Cornidovirineae, family Coronaviridae, subfamily Orthocoronavirinae, genus Gammacoronavirus, subgenus Igacovirus [2]

  • The antigenic variability entails the existence of several serotypes and protectotypes, which translate in a poor cross-protection among genotypes [9], requiring the use of different vaccine combinations in order to broaden the protection spectrum or the development of new vaccines against recently emerged or introduced genotypes [10, 11]

  • The present study investigates the impact of the homologous vaccination application on the evolution of IBV QX genotype (GI-19 lineage) S1 subunit in field conditions, circumventing the above-mentioned limitations and benefiting of the peculiar Italian epidemiological scenario and related control strategies applied in response to QX introduction in this country

Read more

Summary

Introduction

Avian infectious bronchitis is a well-recognized and widespread disease, which entails remarkable economic losses to the poultry industry by inducing respiratory and reproductive signs, decreased productive performances and increased mortality, when nephropathogenic strains or secondary infections are involved [1].The etiological agent, avian infectious bronchitis virus (IBV), is a member of the species avian Coronavirus, order Nidovirales, suborder Cornidovirineae, family Coronaviridae, subfamily Orthocoronavirinae, genus Gammacoronavirus, subgenus Igacovirus [2]. As other positive-sense single-stranded RNA viruses, IBV is able to evolve rapidly and to recombine [1, 7, 8], leading to the emergence of a remarkable genetic and phenotypic variability over time. This heterogeneity poses noteworthy challenges to the Franzo et al Vet Res (2019) 50:92 understanding of IBV epidemiology and its control. Even closely related vaccines can fall into episodes of incomplete protection or vaccine immune-escape because of amino acid substitution in specific antigenic sites [9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call